Novo stock falls after lowered 2026 expectations

Danish pharmaceutical giant Novo Nordisk recorded a revenue of over DKK 309 billion in 2025, showing a 6% growth, as revealed in its annual report. However, growth in the sale of weight loss drugs slowed in the fourth quarter, but Wegovy sales exceeded analyst expectations, reaching DKK 21.9 billion. Despite this success, the company anticipates […]